ネクセラファーマ(株)【4565】の掲示板 2017/06/13〜2017/06/16

次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares has been operating for ten years and has over 115 employees in the UK and 5 employees in Zurich.
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※SOSEI：Heptares、ペプチド作動薬に結合したGLP-1受容体全長の構造を初めて解明。GLP-1ペプチドの分子作用機構と、関連受容体との相互作用を解明する糸口となる知見がNature誌に掲載。(6/1)
※Heptares: We are seeking an experienced Bioinformatician to work with scientists internally and externally across a range of disciplines to advance both our platform technology and our pipeline of new medicines. (6/1update)
※Novartis Spain: Ultiro Breezhaler reinforces its superiority data against Salmeterol / Fluticasone in the prevention of exacerbations in patients with COPD. Reflected in the conclusions of the new GesEPOC 2017 guide. (6/6)
※米国特許：Bicyclic AZA Compounds as Muscarinic M1 Receptor Agonists. (6/6公開)　※米国特許：Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor Agonists. (6/6公開)
※Novartis Greece: Novartis Inpatient for Chronic obstructive pulmonary disease (COPD) is associated with less critical handling errors than other COPD devices, according to a new study. (6/7)
※米国特許出願：Muscarinic M1 Receptor Agonists. (6/8公開)
※ノバルティスファーマ：新たな解析により、ステロイドで治療されているCOPD患者に対する｢ウルティブロ ブリーズヘラー｣の可能性を確認。日本語翻訳版。(6/8)
※HeptaresTL: Nature: A sugar high in structural biology: Four Nature papers describing the receptor structures involved in glucose metabolism hold great promise for finding new ways to treat diabetes. (6/8)
※European Respiratory Journal: Novartis COPD Inhalers More Effectively, New Study Suggests: Novartis COPD inhaler allows patients to receive the full dose of their medication correctly. (6/8)
※QLifePro：ウルティブロ、血中好酸球数が高値のCOPDの一部で、ICSを必要としない可能性を示唆。ICS投与検討時はリスク－ベネフィット評価を個々に実施する必要性を提起。(6/12)
※Pluristem Video: Yaky Yanay, CEO and president of Pluristem Therapeutics, at the Jerusalem Post Annual Conference. (6/12update)
※米国特許：4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators. (6/13公開)
※Protein Data Bank: 5NX2, "Crystal structure of thermostabilised full-length GLP-1R in complex with a truncated peptide agonist at 3.7 A resolution." (6/14 Released)
※Heptares: We are currently recruiting a Lab Support Technician to join our Operations team GPCR. "Closing 6 July 2017." (6/14up)
※Cambridge Independent: AstraZeneca and LMB in Cambridge use one of world’s most advanced microscopes to make breakthrough. A technique that’s being pioneered in Cambridge using a Cryo-Electron Microscope. (6/14)
※Heptares: Publications. (6/15update) ※Heptares: Events. (6/15update)
※Heptares Zurich, Executive Research Director: We are seeking a person with Pharma/Biotech experience to manage and co-ordinate research and administrative operations. (6/16 Recruiting End)
・・・
※MRC LMB: "Cryo-EM: Past, present and future of cryo-EM.": Richard Henderson. (6/19 9:30)
※BIO International Convention, Jun 19-22, San Diego, CA, USA: Barry Kenny (Business Development)
※SOSEI第27回定時株主総会：6月22日(木) 午前10時
※SOSEI平成29年3月期 株主通信：6月下旬予定
※In celebration of the 10th Anniversary of the founding of Heptares Therapeutics: "G protein-coupled receptors: structure-based drug discovery from crystals to the clinic.": 2017/07/13 10.00am - 5.30pm.
(Speakers: Fiona Marshall, Malcolm Weir, Chris Tate, Richard Henderson, Gebhard Schertler, Andreas Plückthun, Rob Cooke, Jon Mason, Tim Tasker, Miles Congreve.)
※Pluristem: Expected Milestones PAD Program: (Closing JV deal with Sosei- Q2-Q3 2017), (Japan pivotal study initiation- H2 2017).
※Allergan: Pipeline Highlights: (CNS: "Muscarinic Receptor M1 Agonist, Entry Ph 1, 2H 2017")
・・・
躍進成長、R&D等の拡充・進捗や中長期成長戦略も着実に進み、次なる展開・進捗が楽しみですね。笑。
控える材料と共にSOSEIの更なる成長･進捗を楽しみましょう。笑。